Canadian Trial Holds Glioblastoma at 6 Months in 82% of 24 Patients With High-Dose Vitamin B3
Updated
Updated · The Cool Down · Jun 27
Canadian Trial Holds Glioblastoma at 6 Months in 82% of 24 Patients With High-Dose Vitamin B3
2 articles · Updated · The Cool Down · Jun 27
Summary
Twenty-four glioblastoma patients in a University of Calgary trial saw 82% remain progression-free at six months after high-dose niacin was added to standard surgery, radiation and chemotherapy.
That interim result was 28% better than earlier studies and cleared the benchmark for the study to continue, giving rare momentum in a cancer whose survival has changed little in 20 years.
Researchers said niacin appears to reverse tumor-driven immune suppression, restoring immune cells' ability to attack cancer; mouse studies had already suggested a survival benefit.
The trial has not changed standard care yet: very high vitamin B3 doses can be dangerous, and the team still needs larger studies, close safety monitoring and review as it works toward 48 participants by 2027.
Can a cheap vitamin succeed where decades of expensive cancer drugs have failed?
If niacin reactivates the immune system, could other cancers also be treated this way?
Niacin Boosts 6-Month Progression-Free Survival to 82% in Glioblastoma: Promising Results from University of Calgary Trial
Overview
University of Calgary researchers are investigating Vitamin B3, or niacin, as a new hope for glioblastoma patients. Early results suggest that niacin may help extend patients’ lives by rejuvenating immune cells, which glioblastoma usually suppresses. This revitalization allows the immune system to better attack and eliminate cancer cells, offering a promising way to overcome the tumor’s strong defenses. While these findings are encouraging, researchers stress the need for careful medical supervision due to possible side effects. Overall, niacin’s ability to boost the body’s natural defenses could mark a significant step forward in glioblastoma treatment.